Invention Grant
US09593162B2 Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
有权
内源化靶向前列腺癌细胞的人单克隆抗体原位
- Patent Title: Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
- Patent Title (中): 内源化靶向前列腺癌细胞的人单克隆抗体原位
-
Application No.: US14486943Application Date: 2014-09-15
-
Publication No.: US09593162B2Publication Date: 2017-03-14
- Inventor: Bin Liu , James D. Marks
- Applicant: The Regents of the University of California
- Applicant Address: US CA Oakland
- Assignee: The Regents of the University of California
- Current Assignee: The Regents of the University of California
- Current Assignee Address: US CA Oakland
- Agency: Weaver Austin Villeneuve & Sampson LLP
- Agent Tom Hunter
- Main IPC: C07K16/30
- IPC: C07K16/30 ; C07K16/18 ; A61K51/10 ; C07K16/28 ; G01N33/574
Abstract:
This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
Public/Granted literature
- US20150071937A1 INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE CANCER CELLS IN SITU Public/Granted day:2015-03-12
Information query
